Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.60 |
| ▸ | MMP13 | P45452 | 1/20 | 0.60 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 4/20 | 0.50 |
| ▸ | MAOB | P27338 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | AXL | P30530 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | VCP | P55072 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10053488 | 0.86 | CHEK2 (0.49) | MMP2MMP13CYP2A6KEAP1KDM4E | |
| SCHEMBL1105989 | 0.84 | HRH3 (0.59) | CYP2A6KEAP1MAOAMAOBALDH1A1 | |
| SCHEMBL13267581 | 0.84 | MAOB (0.55) | CYP2A6KEAP1MAOAMAOBALDH1A1 | |
| SCHEMBL3704183 | 0.82 | CYP2A6 (0.55) | MMP2MMP13CYP2A6KEAP1MAOA | |
| SCHEMBL7906683 | 0.82 | F2 (0.58) | CYP2A6KEAP1 | |
| SCHEMBL27933914 | 0.81 | MMP2 (0.56) | MMP2MMP13ALDH1A1KDM4ELCK | |
| SCHEMBL1651087 | 0.80 | MMP2 (0.66) | MMP2MMP13ALDH1A1KDM4EMEN1 | |
| SCHEMBL25139676 | 0.79 | KDM4E (0.51) | MMP2MMP13CYP2A6KEAP1MAOA | |
| SCHEMBL19058581 | 0.79 | MAOA (0.57) | CYP2A6KEAP1MAOAMAOBALDH1A1 | |
| SCHEMBL554335 | 0.79 | ALDH1A1 (0.66) | CYP2A6KEAP1MAOAMAOBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120252853-A1 | Positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2012-10-04 | — | — | US | claimed |
| WO-2012131031-A1 | NEW POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H. LUNDBECK A/S (DK) | 2012-10-04 | — | — | WO | claimed |
| EP-3305778-B1 | INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-01-19 | — | — | EP | disclosed |
| EP-3305778-A1 | INHIBITORS OF PLASMA KALLIKREIN | Kalvista Pharmaceuticals Limited (GB) | 2018-04-11 | — | — | EP | disclosed |
| EP-2999697-B1 | HETEROCYCLIC DERIVATES | KALVISTA PHARMACEUTICALS LTD (GB) | 2017-04-19 | — | — | EP | disclosed |
| US-9533987-B2 | Heterocyclic derivates | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-01-03 | — | — | US | disclosed |
| US-20160108036-A1 | HETEROCYCLIC DERIVATES | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-04-21 | — | — | US | disclosed |
| EP-2590950-B1 | N-CYCLYL-3-(CYCLYLCARBONYLAMINOMETHYL)BENZAMIDE DERIVATIVES AS RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-10-15 | — | — | EP | disclosed |
| WO-2012131031-A1 | NEW POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H. LUNDBECK A/S (DK) | 2012-10-04 | — | — | WO | disclosed |
| US-20120252853-A1 | Positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2012-10-04 | — | — | US | disclosed |
| US-20120165322-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
| WO-2012006203-A1 | N-CYCLYL-3 - (CYCLYLCARBONYLAMINOMETHYL) BENZAMIDE DERIVATIVES AS RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-12 | — | — | WO | disclosed |
| WO-2010093191-A2 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG LIFE SCIENCES LTD. (KR) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010093191-A2 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG LIFE SCIENCES LTD. (KR) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108036-A1 | HETEROCYCLIC DERIVATES | BDKRB1, KLKB1, BDKRB2 | MMP2 202/4885MMP13 466/4885CYP2A6 1170/4885 |
| US-20120165322-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, RHOA | MMP2 1018/4885MMP13 1410/4885CYP2A6 2553/4885 |
| US-20120252853-A1 | Positive allosteric modulators of nicotinic acetylcholine receptor | CHRNG, CHRNA7, CHRNA2 | MMP2 4614/4885MMP13 4639/4885CYP2A6 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.